Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
No open-market purchases or sales by Vir Biotechnology, Inc. insiders were filed in the last 90 days; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vir Biotechnology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vir Biotechnology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| More Robert J | Director | 517,917Indirect | Aug 12, 2026 | 2 |
| Coughlin Timothy | Director | 16,000 | Jun 10, 2026 | 1 |
| Napolitano Janet | Director | 21,216 | Jun 2, 2026 | 2 |
| Sabatini Brent | SVP, Chief Accounting Officer | 61,902 | Jun 2, 2026 | 5 |
| Bischofberger Norbert W | Director | 21,333 | May 28, 2026 | 1 |
| Hatfield Jeffrey S. | Director | 39,806 | May 28, 2026 | 1 |
| Sigal Charles Elliott | Director | 39,806 | May 28, 2026 | 1 |
| Farid Ramy | Director | 32,000 | May 28, 2026 | 1 |
| Sato Vicki L | Director | 1,078,391 | May 4, 2026 | 9 |
| De Backer Marianne | President and CEO | 286,650Indirect | Apr 30, 2026 | 4 |
| O'Byrne Jason | EVP & Chief Financial Officer | 2,500Indirect | Mar 23, 2026 | 4 |
| Eisner Mark | EVP and Chief Medical Officer | 154,024 | Feb 26, 2026 | 2 |
| de Verneuil Vanina | EVP, General Counsel, Corp Sec | 112,982 | Feb 26, 2026 | 4 |
| SB Investment Advisers (UK) Ltd | 10% Owner | 13,728,924Indirect | Dec 3, 2025 | 11 |
| Softbank Vision Fund (Aiv M1) L.P. | 10% Owner | 13,728,924Indirect | Dec 3, 2025 | 11 |
| SVF Endurance (Cayman) Ltd | 10% Owner | 13,728,924Indirect | Dec 3, 2025 | 11 |
| Ramasastry Saira | Director | 22,619 | Jun 2, 2025 | 0 |
| Scangos George A | Director | 698,239 | Feb 25, 2025 | 0 |
| Hanly Ann M. | EVP & Chief Technology Officer | 117,901 | Feb 25, 2025 | 0 |
| Nelsen Robert | Director | 584,148 | Jun 3, 2024 | 0 |
| Lee Sung | EVP & Chief Financial Officer | 100,492 | Mar 28, 2024 | 0 |
| Pang Phillip | EVP & Chief Medical Officer | 250,111 | Feb 26, 2024 | 0 |
| Rice Steven J. | Chief Administrative Officer | 106,840 | Jun 2, 2023 | 0 |
| Sharp Phillip A | Director | 121,174 | May 24, 2023 | 0 |
| Perez Robert J | Director | 15,806 | May 24, 2023 | 0 |
| Friedl-Naderer Johanna | EVP & Chief Operating Officer | 148,518 | Mar 7, 2023 | 0 |
| Horn Howard | CFO | 230,712 | Feb 24, 2023 | 0 |
| Crandell Keith | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| Bybee Clinton | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Fund IX, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Fund IX Overage, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Partners IX Overage, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Partners IX, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Partners IX, LLC | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| Virgin Herbert | EVP, Research & CSO | 262,500 | Aug 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 22, 2022 (view filing) | Feb 17-18 | 5 days | Scangos George APresident and CEO | SSale | −27.8K | $31.11 | −$863.4K | −19.7%113.0K after | 2 lots |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Virgin HerbertEVP, Research & CSO | SSale | −2.29K | $31.93 | −$73.2K | −2.1%105.4K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Rice Steven J.Chief Administrative Officer | SSale | −1.94K | $31.93 | −$62.0K | −9.4%18.7K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Horn HowardCFO | SSale | −2.39K | $31.93 | −$76.4K | −1.2%200.4K after | |
| Feb 18, 2022 (view filing) | Feb 16-17 | 2 days | Pang PhillipChief Medical Officer | SSale | −8.01K | $31.69 | −$253.8K | −8.2%89.8K after | 2 lots |
| Feb 9, 2022 (view filing) | Feb 8 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $33.94 | −$46.7K | −1.3%107.7K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Pang PhillipChief Medical Officer | SSale | −5.00K | $34.52 | −$172.6K | −5.1%92.8K after | |
| Jan 26, 2022 (view filing) | Jan 25 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $32.46 | −$44.6K | −1.3%107.7K after | |
| Jan 20, 2022 (view filing) | Jan 19 | 1 day | Pang PhillipChief Medical Officer | SSale | −5.00K | $35.06 | −$175.3K | −5.1%92.8K after | 2 lots |
| Jan 20, 2022 (view filing) | Jan 18 | 2 days | Sato Vicki LDirector | SSale | −15.2K | $37.39 | −$567.3K | −1.0%1.54M after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $35.10 | −$48.3K | −1.3%107.7K after | |
| Jan 6, 2022 (view filing) | Jan 5 | 1 day | Pang PhillipChief Medical Officer | SSale | −5.00K | $37.19 | −$186.0K | −5.1%92.8K after | 2 lots |
| Dec 30, 2021 (view filing) | Dec 28 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $39.95 | −$54.9K | −1.3%107.7K after | |
| Dec 22, 2021 (view filing)4:30 PM ET | Dec 20 | 2 days | SB Investment Advisers (UK) Ltd and 2 others10% Owner | SSale | −400.0K | $52.73 | −$21.1M | −1.8%22.2M after | |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Sato Vicki LDirector | SSale | −15.2K | $54.53 | −$827.5K | −1.0%1.55M after | 5 lots |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Pang PhillipChief Medical Officer | SSale | −5.00K | $50.72 | −$253.6K | −5.1%92.8K after | 4 lots |
| Dec 16, 2021 (view filing) | Dec 14-15 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −4.13K | $48.63 | −$200.6K | −3.7%107.7K after | 2 lots |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Pang PhillipChief Medical Officer | SSale | −7.50K | $43.45 | −$325.8K | −7.5%92.8K after | 4 lots |
| Dec 2, 2021 (view filing) | Nov 30 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −15.1K | $49.60 | −$750.2K | −12.3%107.7K after | 2 lots |
| Dec 2, 2021 (view filing) | Nov 30 | 2 days | Rice Steven J.Chief Administrative Officer | SSale | −10.0K | $50.00 | −$500.0K | −32.7%20.6K after | |
| Dec 2, 2021 (view filing) | Nov 30 | 2 days | Napolitano JanetDirector | SSale | −1.44K | $46.25 | −$66.4K | −29.8%3.37K after | |
| Dec 1, 2021 (view filing) | Nov 29 | 2 days | Hanly Ann M.Chief Technology Officer | PPurchase | +11.52 | $43.39 | +$499.85 | New position11.52 after | |
| Nov 30, 2021 (view filing) | Nov 26 | 4 days | Sato Vicki LDirector | SSale | −15.2K | $36.80 | −$558.4K | −1.0%1.57M after | |
| Nov 19, 2021 (view filing) | Nov 17 | 2 days | Pang PhillipChief Medical Officer | SSale | −5.00K | $35.85 | −$179.2K | −4.7%100.3K after | 2 lots |
| Nov 18, 2021 (view filing) | Nov 16 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $32.67 | −$44.9K | −1.3%107.7K after | |
| Nov 4, 2021 (view filing) | Nov 3 | 1 day | Pang PhillipChief Medical Officer | SSale | −5.00K | $36.47 | −$182.3K | −4.7%100.3K after | |
| Nov 3, 2021 (view filing) | Nov 2 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $36.94 | −$50.8K | −1.3%107.7K after | |
| Oct 22, 2021 (view filing) | Oct 20 | 2 days | Pang PhillipChief Medical Officer | SSale | −4.00K | $39.65 | −$158.6K | −3.8%100.3K after | |
| Oct 21, 2021 (view filing) | Oct 19 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $38.87 | −$53.4K | −1.3%107.7K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Sato Vicki LDirector | SSale | −15.2K | $39.56 | −$600.3K | −1.0%1.58M after | 2 lots |
| Oct 7, 2021 (view filing) | Oct 6 | 1 day | Pang PhillipChief Medical Officer | SSale | −5.00K | $34.56 | −$172.8K | −4.6%104.3K after | |
| Oct 6, 2021 (view filing) | Oct 5 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $33.75 | −$46.4K | −1.3%107.7K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −4.13K | $50.00 | −$206.3K | −4.0%99.7K after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Sato Vicki LDirector | SSale | −15.2K | $52.48 | −$796.3K | −0.9%1.60M after | 2 lots |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Pang PhillipChief Medical Officer | SSale | −5.00K | $49.69 | −$248.5K | −4.6%104.3K after | 2 lots |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Virgin HerbertEVP, Research & CSO | SSale | −4.13K | $49.67 | −$204.9K | −4.0%99.7K after | 2 lots |
| Sep 2, 2021 (view filing) | Sep 1 | 1 day | Pang PhillipChief Medical Officer | SSale | −5.00K | $49.58 | −$247.9K | −4.4%109.3K after | 3 lots |
| Aug 31, 2021 (view filing) | Aug 30 | 1 day | Napolitano JanetDirector | SSale | −1.44K | $51.15 | −$73.4K | −29.8%3.37K after | |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −2.75K | $50.00 | −$137.5K | −2.7%99.7K after | |
| Aug 25, 2021 (view filing) | Aug 24 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $48.00 | −$66.0K | −1.4%99.7K after | |
| Aug 24, 2021 (view filing) | Aug 23 | 1 day | Rice Steven J.Chief Administrative Officer | SSale | −10.0K | $50.00 | −$500.0K | −33.3%20.0K after | |
| Aug 24, 2021 (view filing) | Aug 23 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −13.8K | $50.00 | −$687.5K | −12.1%99.7K after | |
| Aug 23, 2021 (view filing) | Aug 19 | 4 days | Sato Vicki LDirector | SSale | −15.2K | $45.05 | −$683.6K | −0.9%1.61M after | 2 lots |
| Aug 20, 2021 (view filing) | Aug 18 | 2 days | Pang PhillipChief Medical Officer | SSale | −5.00K | $42.23 | −$211.2K | −4.4%109.3K after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $41.00 | −$56.4K | −1.4%99.7K after | |
| Aug 5, 2021 (view filing) | Aug 4 | 1 day | Pang PhillipChief Medical Officer | SSale | −5.00K | $34.92 | −$174.6K | −4.4%109.3K after | |
| Aug 2, 2021 (view filing) | Jul 29 | 4 days | More Robert JDirector | SSale | −11.7K | $36.82 | −$429.7K | −24.5%36.0K after | 2 lots |
| Jul 28, 2021 (view filing) | Jul 27 | 1 day | Virgin HerbertEVP, Research & CSO | SSale | −1.38K | $36.72 | −$50.5K | −1.4%99.7K after | |
| Jul 23, 2021 (view filing) | Jul 21 | 2 days | Pang PhillipChief Medical Officer | SSale | −4.63K | $37.44 | −$173.3K | −4.1%109.3K after | |
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Sato Vicki LDirector | SSale | −15.2K | $37.20 | −$564.5K | −0.9%1.63M after | 2 lots |